Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Ward

Orthopaedic Surgery Tucson, AZ Doctor of Osteopathy

NPI 1306289764 CMS profile 741177

6130 N La Cholla Blvd Ste 135A, Tucson, AZ 85741

Open in the dashboard

General payments

$1,718

37 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Ward of Tucson, AZ is reported in the CMS Open Payments database as having received $1,718 across 37 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $469 9
2024 General $145 4
2023 General $90 4
2022 General $427 10
2021 General $100 3
2019 General $487 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Ward
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Steven Ward were reported at $469. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Steven Ward Orthopaedic Surgery median Middle half National median
2019 $487 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $100 $520 $117–$2,495 $132
2022 $427 $598 $128–$2,731 $149
2023 $90 $461 $128–$2,264 $160
2024 $145 $497 $134–$2,475 $164
2025 $469 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $562 10 payments
  2. Medical Device Business Services, Inc. $305 6 payments
  3. Smith+Nephew, Inc. $208 7 payments
  4. DePuy Synthes Sales Inc. $171 5 payments
  5. Innovation Technologies Inc $139 2 payments
  6. Amgen Inc. $122 1 payment
  7. Ethicon US, LLC $81 1 payment
  8. Flexion Therapeutics, Inc. $46 1 payment
  9. Djo, LLC $38 1 payment
  10. Bioventus LLC $16 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,469 35 payments
  2. Travel and Lodging $249 2 payments
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $212 3 payments
  2. Irrisept $139 2 payments
  3. EVENITY $122 1 payment
  4. NA $118 3 payments
  5. ATTUNE $103 3 payments
  6. MAKO Knees, Hips $92 1 payment
  7. HOFFMANN $92 1 payment
  8. STRATAFIX $81 1 payment
  9. Prineo 42 $81 1 payment
  10. SURG - NEW PRODUCT DEVELOPMENT $76 1 payment
  11. Other $617 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

654

Median for Orthopedic Surgery: 203

Drug cost

$4,274

Median for Orthopedic Surgery: $1,433

Branded share of claims

17%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 204 $1,150
Celecoxib Generic 27 $676
Meloxicam Generic 130 $626
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 60 $461
Ondansetron Odt Ondansetron Brand 51 $409
Tramadol Hcl Generic 107 $402
Ibuprofen Generic 38 $295
Gabapentin Generic 14 $132
Methylprednisolone Generic 12 $75
Methocarbamol Generic 11 $48

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 129 billing codes

Paid by Medicare

$300,123

Of which drugs: $6,157

Medicare patients

584

Average age 76

Services billed

4,081

352 women, 232 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 64%
Ischemic heart disease 27%
Depression 27%
Chronic kidney disease 26%
Osteoporosis 23%
Diabetes 22%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 203 1,545 $1,146

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record